• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

OX40 及其配体在癌症中的作用。

OX40 and OX40L Interaction in Cancer.

机构信息

The Mary and Garry Weston Molecular Immunology Laboratory, Thrombosis Research Institute, London- SW3 6LR, United Kingdom.

出版信息

Curr Med Chem. 2021;28(28):5659-5673. doi: 10.2174/0929867328666201229123151.

DOI:10.2174/0929867328666201229123151
PMID:33372866
Abstract

BACKGROUND

OX40 (CD134) and its binding partner, OX40L (CD252), are expressed on activated CD4, CD8 T-cells, and several other lymphoid and non-lymphoid cells. OX40L belongs to a TNF family member, a 34 kDa type II transmembrane protein. The crystallized complex of human OX40 and OX40L is a trimeric contableuration of one OX40L (trimer) and three OX40 monomers. OX40 and OX40L regulate cytokine production from T-cells, antigen-presenting cells, and natural killer (NK) cells, and modulate cytokine receptor signaling.

METHODS

In this review, an updated overview of the structural features of OX40/OX40L and their interactions with cancer are provided.

RESULTS

Recent studies have shown that stimulation of OX40 is useful for therapeutic immunization strategies for cancer. OX40 serves as a secondary costimulatory immune checkpoint molecule; the binding of OX40 to its ligand enhances the augmentation, survival, memory formation, effector function, and recall responses of both CD4+ and CD8+ T-cells.

CONCLUSION

This review highlights that OX40-OX40L interactions play crucial roles in both CD4+ and CD8+ T-cells. Signals through OX40 can abolish the suppressive activity of Tregs, prevent the induction of Tregs from effector T-cells, reduce Foxp3 expression, and induce the proliferation of memory and effector T lymphocytes. Additionally, when transferred into tumor-bearing recipients, they generate proliferation capability and successfully eliminate the established tumor.

摘要

背景

OX40(CD134)及其配体 OX40L(CD252)表达于活化的 CD4、CD8 T 细胞和其他一些淋巴和非淋巴样细胞上。OX40L 属于 TNF 家族成员,是一种 34kDa 的 II 型跨膜蛋白。人 OX40 和 OX40L 的结晶复合物是一个三聚体,由一个 OX40L(三聚体)和三个 OX40 单体组成。OX40 和 OX40L 调节 T 细胞、抗原呈递细胞和自然杀伤(NK)细胞的细胞因子产生,并调节细胞因子受体信号。

方法

在这篇综述中,提供了 OX40/OX40L 的结构特征及其与癌症相互作用的最新概述。

结果

最近的研究表明,刺激 OX40 可用于癌症的治疗性免疫接种策略。OX40 作为一种辅助性免疫检查点分子;OX40 与其配体的结合增强了 CD4+和 CD8+T 细胞的扩增、存活、记忆形成、效应功能和回忆反应。

结论

本综述强调了 OX40-OX40L 相互作用在 CD4+和 CD8+T 细胞中都起着至关重要的作用。通过 OX40 传递的信号可以消除 Treg 的抑制活性,防止效应 T 细胞诱导 Treg 的产生,减少 Foxp3 的表达,并诱导记忆和效应 T 淋巴细胞的增殖。此外,当转移到荷瘤受体中时,它们会产生增殖能力,并成功消除已建立的肿瘤。

相似文献

1
OX40 and OX40L Interaction in Cancer.OX40 及其配体在癌症中的作用。
Curr Med Chem. 2021;28(28):5659-5673. doi: 10.2174/0929867328666201229123151.
2
The significance of OX40 and OX40L to T-cell biology and immune disease.OX40和OX40L对T细胞生物学及免疫疾病的意义。
Immunol Rev. 2009 May;229(1):173-91. doi: 10.1111/j.1600-065X.2009.00766.x.
3
OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.OX40-OX40 配体相互作用在 T 细胞介导的免疫和免疫病理学中的作用。
Adv Immunol. 2010;105:63-98. doi: 10.1016/S0065-2776(10)05003-0.
4
OX40, OX40L and Autoimmunity: a Comprehensive Review.OX40、OX40L与自身免疫:全面综述
Clin Rev Allergy Immunol. 2016 Jun;50(3):312-32. doi: 10.1007/s12016-015-8498-3.
5
Control of immunity by the TNFR-related molecule OX40 (CD134).OX40(CD134)分子对免疫的控制作用。
Annu Rev Immunol. 2010;28:57-78. doi: 10.1146/annurev-immunol-030409-101243.
6
Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.OX40(CD134)的结扎调节异基因骨髓移植受者的移植物抗宿主病(GVHD)和移植排斥反应。
Blood. 2003 May 1;101(9):3741-8. doi: 10.1182/blood-2002-10-3048. Epub 2003 Jan 9.
7
Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells.人活化CD4+和CD8+ T细胞上OX40配体功能表达的要求。
Hum Immunol. 2007 Jul;68(7):563-71. doi: 10.1016/j.humimm.2007.03.012. Epub 2007 Apr 13.
8
The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia.OX40 免疫检查点调节剂及其配体 OX40L 在 NK 细胞免疫监视和急性髓系白血病中的作用。
Cancer Immunol Res. 2018 Feb;6(2):209-221. doi: 10.1158/2326-6066.CIR-17-0212. Epub 2018 Jan 10.
9
Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases.组成性OX40/OX40配体相互作用诱导自身免疫样疾病。
J Immunol. 2002 Oct 15;169(8):4628-36. doi: 10.4049/jimmunol.169.8.4628.
10
OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.胶质母细胞瘤中表达的OX40配体根据微环境调节适应性免疫:成功免疫治疗的线索
Mol Cancer. 2015 Feb 15;14:41. doi: 10.1186/s12943-015-0307-3.

引用本文的文献

1
Transcriptomic Profiling of the Immune Response in Orthotopic Pancreatic Tumours Exposed to Combined Boiling Histotripsy and Oncolytic Reovirus Treatment.原位胰腺癌在接受联合沸腾组织粉碎术和溶瘤呼肠孤病毒治疗后免疫反应的转录组分析
Pharmaceutics. 2025 Jul 22;17(8):949. doi: 10.3390/pharmaceutics17080949.
2
Prognostic value of the co-stimulatory molecule OX40 expression in Extranodal Natural Killer/T-cell Lymphoma.共刺激分子OX40表达在结外自然杀伤/ T细胞淋巴瘤中的预后价值
Ann Med. 2025 Dec;57(1):2550583. doi: 10.1080/07853890.2025.2550583. Epub 2025 Aug 23.
3
Stemness-driven clusters in ovarian cancer: immune characteristics and prognostic implications.
卵巢癌中由干性驱动的簇:免疫特征及预后意义
Front Oncol. 2025 Jun 11;15:1577283. doi: 10.3389/fonc.2025.1577283. eCollection 2025.
4
Immunomodulation on tumor immune microenvironment in acquired targeted therapy resistance and implication for immunotherapy resistance.获得性靶向治疗耐药中肿瘤免疫微环境的免疫调节及其对免疫治疗耐药的影响
Transl Oncol. 2025 Apr;54:102353. doi: 10.1016/j.tranon.2025.102353. Epub 2025 Mar 8.
5
Endothelial OX40 activation facilitates tumor cell escape from T cell surveillance through S1P/YAP-mediated angiogenesis.内皮细胞OX40激活通过S1P/YAP介导的血管生成促进肿瘤细胞逃避T细胞监视。
J Clin Invest. 2025 Mar 3;135(5):e186291. doi: 10.1172/JCI186291.
6
Pan-cancer analysis shows that TNFSF4 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including liver cancer.泛癌分析表明,TNFSF4是包括肝癌在内的多种癌症类型的潜在预后和免疫治疗生物标志物。
BMC Cancer. 2025 Jan 17;25(1):100. doi: 10.1186/s12885-025-13479-4.
7
SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity.SHR-1806,一种强效的 OX40 激动剂,可促进 T 细胞介导的抗肿瘤免疫。
Cancer Biol Ther. 2024 Dec 31;25(1):2426305. doi: 10.1080/15384047.2024.2426305. Epub 2024 Nov 14.
8
Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment.B细胞中的免疫检查点:开启癌症治疗的新潜力
Adv Sci (Weinh). 2024 Dec;11(47):e2403423. doi: 10.1002/advs.202403423. Epub 2024 Nov 7.
9
A multifunctional targeted nano-delivery system with radiosensitization and immune activation in glioblastoma.一种具有放射增敏和免疫激活功能的多功能靶向纳米递药系统用于治疗脑胶质瘤。
Radiat Oncol. 2024 Sep 12;19(1):119. doi: 10.1186/s13014-024-02511-9.
10
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy.增强癌症治疗中抗 PD-1 抗体、抗 PD-L1 抗体和抗 CTLA-4 抗体治疗效果的策略。
J Transl Med. 2024 Aug 9;22(1):751. doi: 10.1186/s12967-024-05552-6.